Osheru Secures $4.7 Million Seed Funding to Advance Ziplyft Device for Blepharoplasty Surgery
Osheru announced the completion of a $4.7 million funding round to accelerate the development and commercialization of its Ziplyft device for blepharoplasty surgery.
Blepharoplasty, a procedure aimed at rejuvenating the appearance of the eyelids, remains one of the most sought-after cosmetic surgeries in the U.S. particularly with the increase in video calls and selfies, according to Osheru. The Ziplyft device is designed to address challenges associated with conventional blepharoplasty procedures, including extended recovery times and risk of complications such as wound dehiscence and asymmetry. Ziplyft aims to reduce downtime and enhance aesthetic outcomes through its proprietary design.
"This $4.7 million funding marks a pivotal moment for Osheru," Patricia Buehler, MD, MPH, CEO of Osheru, said in a company news release. "It demonstrates the strong confidence in Ziplyft from both the medical community and investors, validating our vision to revolutionize blepharoplasty with cutting-edge technology."
The round was led by individuals and family offices, including investment from Nike Co-Founder Phil Knight. Additional investors include Oregon ToughTech BreakThrough Fund managed by ONAMI for Business Oregon; and SOPHINCAP, the corporate venture fund of Laboratorios Sophia, an international ophthalmology company.
Osheru also announced the appointment of John Garland as Chief Commercial Officer. A veteran executive in the ophthalmology industry, Mr. Garland brings decades of experience in medical device innovation and commercialization, having managed global operations in 70 countries.
Dr. Buehler received the 'Eyecelerator People’s Choice Award' earlier this year for the Ziplyft and its advancements in blepharoplasty techniques. Last year, she won 'The Winning Pitch Challenge' for best early-stage company at the American Society of Cataract and Refractive Surgeons (ASCRS).
Osheru said commercialization of the Ziplyft is slated for 2025. For more information, visit www.osheru.com.